11,461 Shares in Eli Lilly and Company (NYSE:LLY) Bought by Vista Investment Partners II LLC

Vista Investment Partners II LLC acquired a new position in shares of Eli Lilly and Company (NYSE:LLY) in the 4th quarter, HoldingsChannel reports. The institutional investor acquired 11,461 shares of the company’s stock, valued at approximately $8,848,000. Eli Lilly and Company comprises approximately 5.2% of Vista Investment Partners II LLC’s holdings, making the stock its biggest position.

Several other hedge funds and other institutional investors have also modified their holdings of LLY. Independent Advisor Alliance raised its holdings in Eli Lilly and Company by 11.1% during the fourth quarter. Independent Advisor Alliance now owns 43,968 shares of the company’s stock valued at $33,943,000 after buying an additional 4,385 shares in the last quarter. Altiora Financial Group LLC raised its holdings in Eli Lilly and Company by 52.7% during the fourth quarter. Altiora Financial Group LLC now owns 974 shares of the company’s stock valued at $752,000 after buying an additional 336 shares in the last quarter. Paragon Private Wealth Management LLC raised its holdings in Eli Lilly and Company by 7.2% during the fourth quarter. Paragon Private Wealth Management LLC now owns 1,323 shares of the company’s stock valued at $1,021,000 after buying an additional 89 shares in the last quarter. Meriwether Wealth & Planning LLC bought a new position in Eli Lilly and Company during the fourth quarter valued at about $371,000. Finally, Johnson Investment Counsel Inc. raised its holdings in Eli Lilly and Company by 1.8% during the fourth quarter. Johnson Investment Counsel Inc. now owns 34,597 shares of the company’s stock valued at $26,709,000 after buying an additional 628 shares in the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Down 4.8 %

NYSE LLY opened at $868.59 on Monday. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00. The stock’s 50 day moving average is $826.63 and its two-hundred day moving average is $847.24. The company has a market capitalization of $823.57 billion, a price-to-earnings ratio of 74.17, a PEG ratio of 1.40 and a beta of 0.34. Eli Lilly and Company has a 1-year low of $711.40 and a 1-year high of $972.53.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. Equities analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company declared that its board has initiated a share repurchase plan on Monday, December 9th that permits the company to repurchase $15.00 billion in shares. This repurchase authorization permits the company to reacquire up to 2% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s management believes its stock is undervalued.

Wall Street Analyst Weigh In

LLY has been the topic of several recent research reports. Leerink Partners set a $950.00 target price on Eli Lilly and Company in a report on Friday, January 17th. Truist Financial lifted their price objective on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a “buy” rating in a research note on Monday, February 3rd. Citigroup dropped their price objective on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating on the stock in a research note on Tuesday, January 28th. Wolfe Research started coverage on Eli Lilly and Company in a research note on Friday, November 15th. They issued an “outperform” rating and a $1,000.00 price objective on the stock. Finally, Berenberg Bank set a $970.00 price objective on Eli Lilly and Company in a research note on Thursday, January 16th. Three investment analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. According to MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and an average price target of $1,007.50.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.